You are here
Real-time Modulated Imaging for Assessment of Tissue Viability Prior to Skin Grafts
Award Information
Agency: Department of Defense
Branch: Defense Health Program
Contract: W81XWH-17-C-0171
Agency Tracking Number: H17A-006-0042
Amount:
$146,600.00
Phase:
Phase I
Program:
STTR
Solicitation Topic Code:
DHA17A-006
Solicitation Number:
2017.0
Timeline
Solicitation Year:
2017
Award Year:
2017
Award Start Date (Proposal Award Date):
2017-08-01
Award End Date (Contract End Date):
2018-02-28
Small Business Information
17151 Gillette Ave, Irvine, CA, 92614
DUNS:
603130928
HUBZone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Principal Investigator
Name: Amaan Mazhar
Title: VP Research and Development
Phone: (949) 596-7512
Email: amaan.mazhar@modulatedimaging.com
Title: VP Research and Development
Phone: (949) 596-7512
Email: amaan.mazhar@modulatedimaging.com
Business Contact
Name: Frederick Ayers
Phone: (949) 596-7493
Email: fred.ayers@modulatedimaging.com
Phone: (949) 596-7493
Email: fred.ayers@modulatedimaging.com
Research Institution
Name: Regents of the University of Califo
Contact: David Cuccia
Address: Applied Innovation, 5141 Calif
Irvine, CA, 92612
Phone: (949) 596-7492
Type: Nonprofit college or university
Contact: David Cuccia
Address: Applied Innovation, 5141 Calif
Irvine, CA, 92612
Phone: (949) 596-7492
Type: Nonprofit college or university
Abstract
There is a lack of quantitative tools to accurately map tissue viability in a rapid and quantitative manner so a surgeon can properly excise tissue prior to grafting. Spatial Frequency Domain Imaging (SFDI) is an optical method that has been shown to be a reliable method for physiology assessment - particularly for burn depth. SFDI measures of tissue structure (scattering) and function (hemoglobin, oxygen saturation, edema) give unique insight into tissue health due to widefield diagnostic capabilities over large curved surfaces and different skin tones. Currently, our company has a FDA cleared cart-based system with indications for measuring oxygen levels in patients who have circulatory compromise. In Phase 1 of this effort, we will partner with University of California, Irvine and build a benchtop SFDI system that utilizes recent advances to test a compact, portable, lightweight version of the system suited for tissue viability measurement as burn surgeons excise tissue. We will directly compare the performance of our device to our FDA-cleared system in a series of validated phantom studies. Upon conclusion of Phase 1, we will be in position to build a clinic-ready system in Phase II for preclinical and clinical burn tissue viability studies. * Information listed above is at the time of submission. *